

**Docket #:** S19-257

# **Novel compounds inhibit phospholipid synthesis in cancer**

## **Disease indication**

*Cancer:* Renal cell carcinoma (RCC), hepatocellular carcinoma (HCC)

**Drug format:** Small molecule compounds, alone or in combination with other chemotherapeutic drugs

**Drug class:** First-in-class

**Target:** Enzymes in phospholipid metabolic pathway

## **Research stage and Preliminary data**

The inventors demonstrated that various lipogenesis inhibitors suppress cancer proliferation in RCC and HCC lines.

*Continued research:* The inventors continue to develop SAR for development candidate.

**Background:** Previous studies have shown that lipid metabolism is frequently perturbed in cancers. Using desorption electrospray mass spectrometry (DESI-MSI), the inventors showed that phospholipid metabolism is altered.

**Mode of action:** Inhibiting phospholipid metabolism disrupts cancer metabolism, suppressing cancer proliferation. To date, the inventors have demonstrated results for HCC and RCC.

## **Advantages**

- First-in-class approach with potential for treating a wide range of cancers

- This is a novel target in oncology

## Patents

- Published Application: [WO2021035031](#)
- Published Application: [20220315528](#)

## Innovators

- Arvin Gouw
- Steven Schow
- Robert Greenhouse
- Toni Kline
- Dean Felsher

## Licensing Contact

### Sam Rubin

Licensing Associate, Life Science

[Email](#)